Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an example - PubMed (original) (raw)
Review
Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an example
Thomas Ming Swi Chang. Artif Cells Blood Substit Immobil Biotechnol. 2006.
Abstract
The original artificial red blood cells have evolved into oxygen carriers in the form of polyhemoglobin and conjugated hemoglobin. Clinical conditions requiring only oxygen carriers are responding well to these types of oxygen carriers without the need for a complete artificial red blood cell. For those conditions requiring more than just oxygen carriers, new generations of polyhemoglobin containing antioxidant enzymes are being developed. Though a complete artificial red blood cell comparable to red blood cell is still a dream, development in lipid membrane artificial red blood cells and biodegradable polymeric nano artificial red blood cells are steps towards this possibility. The many years of neglect on basic research in the area of blood substitutes have resulted in the lack of important basic knowledge needed for the rapid development of blood substitutes suitable for clinical use. This is further hampered by the mistaken conception that blood substitute is a single entity. We need to look at blood substitutes as consisting of progressively more complicated entities, e.g. oxygen carriers, oxygen carriers with antioxidant activity, and complete red blood cell substitutes. Each of these entities is not applicable to all clinical conditions, but is suitable for specific applications.
Similar articles
- Oxygen carriers.
Chang TM. Chang TM. Curr Opin Investig Drugs. 2002 Aug;3(8):1187-90. Curr Opin Investig Drugs. 2002. PMID: 12211412 Review. - Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others.
Kim HW, Greenburg AG. Kim HW, et al. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(6):537-50. doi: 10.1080/10731190600973725. Artif Cells Blood Substit Immobil Biotechnol. 2006. PMID: 17090427 Review. - [Current aspects in red blood cell substitutes].
Wang Y, Pan J, Yu Y. Wang Y, et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Jun;21(3):490-4. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004. PMID: 15250164 Review. Chinese. - Polymer/hemoglobin assemblies: biodegradable oxygen carriers for artificial red blood cells.
Li T, Jing X, Huang Y. Li T, et al. Macromol Biosci. 2011 Jul 7;11(7):865-75. doi: 10.1002/mabi.201000469. Epub 2011 Feb 10. Macromol Biosci. 2011. PMID: 21312333 - Hemoglobin-based red blood cell substitutes.
Chang TM. Chang TM. Artif Organs. 2004 Sep;28(9):789-94. doi: 10.1111/j.1525-1594.2004.07394.x. Artif Organs. 2004. PMID: 15320941 Review.
Cited by
- Erythroid Differentiation of Induced Pluripotent Stem Cells Co-cultured with OP9 Cells for Diagnostic Purposes.
Roh J, Kim S, Cheong JW, Jeon SH, Kim HK, Kim MJ, Kim HO. Roh J, et al. Ann Lab Med. 2022 Jul 1;42(4):457-466. doi: 10.3343/alm.2022.42.4.457. Ann Lab Med. 2022. PMID: 35177566 Free PMC article. - Mechanisms of slower nitric oxide uptake by red blood cells and other hemoglobin-containing vesicles.
Azarov I, Liu C, Reynolds H, Tsekouras Z, Lee JS, Gladwin MT, Kim-Shapiro DB. Azarov I, et al. J Biol Chem. 2011 Sep 23;286(38):33567-79. doi: 10.1074/jbc.M111.228650. Epub 2011 Jul 30. J Biol Chem. 2011. PMID: 21808057 Free PMC article. - Hypoxia and radiation therapy: past history, ongoing research, and future promise.
Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Rockwell S, et al. Curr Mol Med. 2009 May;9(4):442-58. doi: 10.2174/156652409788167087. Curr Mol Med. 2009. PMID: 19519402 Free PMC article. - The variant Creutzfeldt-Jakob Disease: Risk, uncertainty or safety in the use of blood and blood derivatives?
Liras A. Liras A. Int Arch Med. 2008 Jun 23;1(1):9. doi: 10.1186/1755-7682-1-9. Int Arch Med. 2008. PMID: 18573217 Free PMC article.